INTRODUCTION
Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF) is a potent phospholipid mediator involved in a variety of pathophysiological events, e.g. inflammation, pulmonary and cardiovascular disorders [1] [2] [3] . PAF is produced endogenously in pathological conditions and also upon stimulation of various cells and tissues [2] [3] [4] . The effects of extracellular PAF are mediated by interaction of PAF with specific cell membrane receptors [5, 6] . Radioligand-binding studies using [3H] PAF have demonstrated specific receptors for PAF in platelets [7, 8] , neutrophils [9, 10] , lymphocytes [11, 12] , monocytes [13] , macrophages [14] , human lung tissues [15] , rat liver tissues [16] and rat brain tissues [17] . The PAF receptor from guinea-pig lung was recently cloned by functional expression and showed homology to the G-protein-coupled receptors with seven transmembrane-spanning segments [18] . The binding of PAF to its receptor initiates a cascade of biochemical events, including phospholipid turnover, activation of protein kinase C, increase in intracellular Ca2l concentration ([Ca2+] 2), and generation and release of other mediators (e.g. eicosanoids) [3, 5, 19] . Specific PAF receptor antagonists inhibit PAF-induced responses [20, 21] .
PAF has been implicated in the pathogenesis of several pulmonary diseases and in inflammatory disorders such as asthma [22] . Pulmonary airway epithelium has been reported to synthesize PAF [23] as well as eicosanoids (e.g. prostaglandins, leukotrienes etc.) upon stimulation [24] , suggesting involvement of the epithelial cells in pathological processes PAF via specific receptors may impact on development of airway inflammation, because the responses of airway epithelial cells to PAF could amplify the injury effects of PAF on the inflamed airway via the generation ofmore mediators. Although a previous study has demonstrated specific binding sites for PAF in human lung tissue homogenates [15] , it is unknown if airway epithelial cells express PAF receptors.
Since the effects of extracellular PAF are mediated by specific cell membrane receptors [5] , understanding of regulation of PAF receptor and the PAF-receptor-mediated signalling mechanism would provide insight into the pathogenesis and therapy of PAFinvolved inflammatory diseases such as asthma. However, knowledge ofregulatory factors that affect specific PAF receptors and subsequent cellular responses is very limited. Generally, any factor decreasing PAF binding to its receptor or subsequent PAF-receptor-mediated signal transduction would play a role in anti-inflammation. Fish oil enriched with eicosapentaenoic acid cells to C1- [30,3 1] . The relationship between the C1-impermeability and the inflammatory process in the epithelial cell is not known. Whether or not changes in ion conductance across the cell membrane can alter inflammatory reactions by affecting the action of inflammatory mediators such as PAF is also unknown. Various univalent and bivalent cations have been found to exert regulatory effects on PAF receptor binding [32] .
Moreover, cation-channel blockers, such as Ca2+-channel blockers [33] [34] [35] and Na+-channel blockers [36] , have been shown to inhibit PAF binding to platelets. However, it is unknown whether Cl-channel blockers affect PAF receptor binding.
The 
Cell Isolaton and culture
Isolation and primary culture of human airway epithelial cells were carried out as previously described [37] . Epithelial cells were isolated from fresh human nasal turbinates with protease (0.1 %, Type 14) and then plated on collagen-coated plates with culture medium (Dulbecco's modified Eagle's/F12, hormones, antibiotics, 1 % fetal-bovine serum). Cells were cultured at 37 'C in a 5 %-CO2 atmosphere and 98 % relative humidity in a tissueculture incubator (model 3173, Forma Scientific) until the cells grew to confluence (usually 5-7 days) . Cultures with an epithelialcell purity of more than 90 % were used for binding assay. To modify the membrane fatty acid profile, 100 ,M fatty acid bound to BSA was added to serum-free culture medium as described previously [28] . After 6 h of incubation with different fatty acids, the cells were harvested and subjected to binding assay, [Ca2l] , measurement and fatty acid analysis. Cell viability was not affected by this concentration of fatty acid.
[3H]PAF binding assay PAF binding was performed by using cell suspensions, as most receptors on the epithelial cell are situated in the basolateral membrane [38] . Cells were detached with 0.05 % trypsin/EGTA, washed twice with 10 % (v/v) fetal-bovine serum culture medium (as above) and incubated at 37 'C for at least 1 h before they were used for binding. 
Lipid analysis
The fatty acid composition of membrane phospholipids was analysed as described previously [41] . Cell total lipid was extracted with chloroform: methanol (2:1, v/v) and separated into phospholipid and neutral lipid by t.l.c. Fatty acids of the phospholipid fraction were methylated and fatty acid methyl esters were analysed by g.l.c. using a fully automated Varian Vista 6000 GLC apparatus equipped with a flame-ionization detector. This procedure quantified all fatty acids. The chromatography utilized a fused-silica BP20 capillary column (25 M x 0.25 mm internal diam.). Heliulm was used as the carrier gas at a flow rate of 1.8 ml/min, by using a splitless injection. The initial oven temperature was 150 'C, increased to 190 'C at 20 'C/min and held for 23 min, then increased to 220 'C at 2 'C/min for a total analysis time of 40 ure 1). The kinetics of PAF binding is similar to that found in monocytes [13] and lymphoblastoid cells [12] . Non [13] and human Raji lymphoblasts [11] , but greater than that found in neutrophils [9] and platelets [7] . The Kd for PAF observed in the epithelial cell is very close to that found in human lymphoblasts [11, 12] , higher than that found in human neutrophils [9] and human lung homogenates [15] , but lower than that found in human monocytes [13] and human platelets [7] .
The specificity of PAF binding was established by competition studies utilizing WEB2086, a known potent PAF-receptor antagonist [22] , and lyso-PAF. WEB2086 (25 1sM Effects of Ion-channel blockers on PAF binding To assess the effect of Ca2+-and Na+-channel blockers on PAF binding to human airway epithelial cell, different concentrations of verapamil, a Ca2+-channel blocker, or amiloride, a Na+-channel blocker, were added to the medium and incubated with cells for 15 min at 37°C, and then specific binding of PAF to the cells was assayed at 4 'C. It was observed that both verapamil and amiloride inhibited PAF binding, but verapamil was much more potent than amiloride ( Figure 6 ). The inhibition of PAF binding by verapamil and amiloride was dose-dependent, with a IC50 of approx. 4-5 ,uM and 0.2 mM respectively ( Figure 6 ).
Scatchard analysis revealed that verapamil and amiloride decreased PAF-receptor binding affinity and the receptor number ( Figure 7) . These results are similar to those found in previous studies with platelets [33, 35] .
Diphenylamine-2-carboxylate (DPC) has been reported to be a Cl--channel blocker in human airway epithelial cells [44] . To test if DPC affects PAF binding, DPC was added to the cell 15 revealed that this agent increased PAF receptor number, but did not affect binding affinity, apparently (Figure 9 ). 
Effects of fatty acid supplementation
It is evident that PAF binding to its membrane receptor can be altered by modifying the membrane fatty acid composition. Previous studies have demonstrated a close association between fatty acids and cell signalling [46] . Non-esterified fatty acids have been shown to act as modulators and/or second messengers of signal transduction [46] . Fatty acids can directly interact with steroid hormones [43] . C20:5,3 can decrease binding of the angiotensin II receptor [47] , the low-density lipoprotein receptor [48] , the thromboxane A2 receptor [49] and the leukotriene B4 receptor [50] , as well as related receptor-mediated responses. In terms of an effect of lipid on the PAF receptor, a previous study [51] showed that incubation of monocytic U937 cells with low-density lipoprotein for 24 h increased the number of PAF receptors. In the same cell type, another study showed that C22:6,3 (10,uM) decreased the PAF-induced increase in
[Ca2+]6 [52] . Dietary 03 polyunsaturated fatty acid was found to inhibit PAF-mediated formation of InsP, in human neutrophils [29] . Similarly, supplementation with fish oil significantly inhibited both the [Ca2+], response and InsP3 formation in response to PAF in rat Kupffer cells [28] . Together, these observations and our present findings strongly suggest that there may be an interaction between fatty acid and PAF-mediated signal-transduction pathways. Our results further suggest that the effect of 03 fatty acid on PAF-mediated signal transduction may occur at the ligand-receptor level.
The mechanism by which 03 fatty acid affects PAF binding activity in the cell is not known. It is possible that the mechanism involves direct interaction between C20:5,3 and the receptor; or C20:5<,3 may bind to the receptor and change receptor conformation, decreasing the availability of binding sites; or the mechanism may involve change in properties of membrane lipid by modifying membrane lipid-bilayer structure, altering receptor conformation or turnover. It is also conceivable that C20:5,,3
An suppresses expression of a gene encoding a receptor component. In addition, it is possible that the decreased PAF binding observed in the cells supplemented with C20 is due to blocking Ca2+ influx, because a Ca2+-channel blocker was found to decrease PAF binding.
We propose that suppression of signal transduction at the level of PAF-receptor binding and the consequent decrease in cellular responsiveness to inflammatory stimuli may provide a novel mechanism by which C20:5.3 produces an anti-inflammatory effect, before its suppression of inflammatory mediator generation.
Effects of Ion-channel blockers
In the present study a Ca2+-channel blocker (verapamil) and a Na+-channel blocker (amiloride) inhibited PAF binding to human airway epithelial cells, whereas a Cl--channel blocker (DPC) increased PAF binding to the cells. Previous studies have demonstrated that verapamil inhibited PAF binding to human platelets [33, 35] and human neutrophils [34] . Valone [33] reported that verapamil inhibited PAF binding to human platelets in a dose-dependent manner, with 50 % inhibition (IC50) at 63 + 12 ,uM. Scatchard analysis revealed that verapamil decreased PAF-receptor binding affinity, but increased the receptor number in platelets, suggesting that this agent acts in competitive and non-competitive mechanisms. Similar results have been found in human neutrophils, except that the IC50 is higher (95 + 14 ,uM) [34] . On the other hand, Wade et al. [35] reported that verapamil inhibited PAF binding to human platelets, with IC50 32 + 7 uM and, based on the observation that the agent decreased PAFreceptor binding affinity without affecting receptor number, suggested that the effect is competitive. In the present study, we found that verapamil inhibited PAF binding to human airway epithelial cells, with IC50 4-51M; Scatchard analysis of PAF binding in the presence of verapamil indicated that this agent decreased both PAF-receptor binding affinity and PAF receptor number. This discrepancy in potency and mechanism of action of verapamil observed in different studies may be attributed to differences in receptors in different cell types and/or differences in the experimental conditions. Our findings that both affinity and binding site were altered by verapamil support the suggestion that the mechanism by which Ca2+-channel blockers inhibit PAF binding is probably more complex than simple competition for receptor binding. It is possible that blocking Ca2+ influx and subsequently changing [Ca2+] , by a Ca2+-channel blocker contribute, at least in part, to its effect on PAF binding. PAF binding to its receptor may be dependent on [Ca2+]1, since an increase in extracellular Ca2+ concentration enhances PAF binding [32] . It is also possible that a Ca2+ channel is coupled with the PAF receptor and regulates the receptor binding activity. However, the exact mechanism by which Ca2+-channel blockers inhibit PAF binding remains to be studied.
Similarly to the Ca2+-channel blocker, amiloride, a Na+-channel blocker, also has inhibitory effects on PAF binding, but it was less effective than verapamil. This result is consistent with previous findings that amiloride and its analogues inhibit the specific PAF binding to rabbit platelet membrane [36] . Amiloride has been proved to be an effective drug in improving the pulmonary conditions in cystic fibrosis [53] . The effect of amiloride may be in part due to its inhibitory effect on PAF binding, in addition to inhibition of Na+ and water absorption.
In terms of the effect of the Cl-channel blocker on PAF 
